Shares in BioXcel Therapeutics rose more than 31% in early trading today after the biotech said an independent audit of a phase 3 trial of its Alzheimer’s disease therapy
BioXcel Therapeutics has claimed its first product approval, getting a green light from the FDA for Igalmi as a treatment for agitation in people with schizophrenia or bipolar disorder.